This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(MedPage Today) -- PHOENIX -- Sooner is better for intravenous thrombolysis (IVT) given before mechanical thrombectomy for acute ischemic stroke, a meta-analysis of patient-level data from randomized controlled trials showed. While the overall.
UVA Health's Karen Johnston, MD, the SHINE trial leader, was pleased to see the new insights into best practices for stroke care. These data from the SHINE trial continue to inform the national stroke community about potential approaches to treating hyperglycemic stroke patients to assure better outcomes,” she said.
10, 2024 — Royal Philips and the World Stroke Organization (WSO) have published a policy paper calling for a revolution in stroke care to make a real difference to the lives of millions and bring significant economic benefits worldwide. Yet, access to thrombectomy remains the exception rather than the norm in global stroke care.
BackgroundIntravenous thrombolysis (IVT) is an effective stroke therapy that remains underused. Finally, sensitivity analysis for idarucizumab, National Institutes of Health Stroke Scale, and timing of DOAC administration was completed. Journal of the American Heart Association, Ahead of Print. versus 3.5%; OR, 0.95 [95% CI, 0.67–1.36]),
Kulcsar, University Hospital Zurich milla1cf Mon, 02/26/2024 - 12:13 February 26, 2024 — Ischemic strokes are a major health burden. Many stroke patients recover poorly despite timely treatment To treat these symptoms and restore blood flow to the brain, the obstructed vessel needs to be “declogged”, or recanalized.
Findings from the highly-anticipated MOST (Multi-Arm Optimization of StrokeThrombolysis) trial were presented on the first day of the American Stroke Association’s International Stroke Conference, ISC 2024, being held through Feb. A lot of our approaches in stroke treatment were learned from how we treat heart attacks.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP118-AWMP118, February 1, 2025. Background and Purpose:Thrombolysis can improve outcome in patients with acute ischemic stroke. Properties of the formed thrombus may influence thrombolysis efficiency and impede recanalization success.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP33-ATMP33, February 1, 2025. Introduction:Acute ischemic stroke (AIS) with large vessel occlusion (LVO) benefits from mechanical thrombectomy (MT), but the majority of Americans require interhospital transfer for MT. The mean time from LKN to thrombolysis was 2.2 years (range, 25.1
(MedPage Today) -- PHOENIX -- Adjunctive thrombolysis with either argatroban or eptifibatide for acute ischemic stroke did not boost efficacy and contributed to risk, the MOST trial showed. When given after starting alteplase (Activase) or tenecteplase.
What is the association of treatment with intravenous thrombolysis (IVT) plus thrombectomy versus thrombectomy alone and outcomes modification by the time from stroke symptom onset to treatment?
Stroke, Volume 56, Issue Suppl_1 , Page ATP8-ATP8, February 1, 2025. Introduction:Treatment of acute stroke has its clear rules and established standards. The neurological deficit corresponded to 5 points in the median NIHSS after a previous stroke, 11 points at the time of recurrence, and 7 points after rescue therapy.
Stroke, Volume 56, Issue Suppl_1 , Page ATP25-ATP25, February 1, 2025. Background:Previous study found that compared with thrombolysis, antiplatelet did not improve outcomes but reduce the risk of symptomatic intracranial hemorrhage(sICH) for mild acute ischemic stroke(AIS) defined as National Institutes of Health Stroke Scale score 0 to 5.
Stroke, Volume 56, Issue Suppl_1 , Page AWP11-AWP11, February 1, 2025. Introduction:Stroke is a leading cause of disability and mortality worldwide, with thrombolysis as a critical treatment. Studies aiming to assess the outcomes of thrombolysis after ischemic stroke in LMIC were selected.
Stroke, Volume 56, Issue Suppl_1 , Page AWP13-AWP13, February 1, 2025. Introduction:Strokes affecting the posterior circulation (PCS) account for 20% of all ischemic strokes. The number of stroke mimics presenting with isolated dizziness who received thrombolysis was 11 in 2021, 16 in 2022, 9 in 2023, and 11 in 2024.
Stroke, Ahead of Print. Background:Stroke with unknown time of onset can be categorized into 2 groups; wake-up stroke (WUS) and unwitnessed stroke with an onset time unavailable for reasons other than wake-up (non–wake-up unwitnessed stroke, non-WUS).
Stroke, Volume 56, Issue Suppl_1 , Page A4-A4, February 1, 2025. Introduction:The tenecteplase versus standard of care for minor ischemic stroke with proven occlusion (TEMPO-2) trial showed that patients presenting with minor deficits up to 12 h do not benefit from intravenous thrombolysis. vs control 2.1%, P=0.005.
Stroke, Volume 56, Issue Suppl_1 , Page ADP3-ADP3, February 1, 2025. Background:Current guidelines for ischemic stroke recommend initiating intravenous thrombolytic therapy within 4.5 hours after stroke onset or the last known well time. These modalities can identify viable brain tissue beyond the 4.5-hour h to standard of care.
Stroke, Volume 56, Issue Suppl_1 , Page AHUP6-AHUP6, February 1, 2025. Introduction:Prior studies have demonstrated social determinants of health (SDoH) are associated with reduced rates of intravenous thrombolysis (IVT) for acute ischemic stroke (AIS), including in disadvantaged populations.
Stroke, Volume 56, Issue Suppl_1 , Page ATP299-ATP299, February 1, 2025. Introduction:Prior studies have demonstrated social determinants of health (SDH) are associated with reduced rates of intravenous thrombolysis (IVT) for acute ischemic stroke (AIS), including in disadvantaged populations.
Stroke, Volume 56, Issue Suppl_1 , Page AWP9-AWP9, February 1, 2025. Background:Acute ischemic stroke can result from extracranial arterial dissection. The effectiveness and safety of intravenous thrombolysis (IVT) for acute ischemic stroke in these cases, particularly those involving large vessel occlusions, are debated.
Intravenous tenecteplase has been shown to be noninferior to alteplase, with a meta-analysis suggesting superiority,1 and although tenecteplase has been used off label, it is replacing alteplase as the preferred thrombolytic agent for the treatment of acute stroke. Aside from the use of thrombolysis for stroke on awakening.
Stroke: Vascular and Interventional Neurology, Ahead of Print. Among 51% of countries surveyed, no acute thrombolytic treatment was provided for acute stroke in the 2021 calendar year. Most respondents (88%) agreed there were barriers to acute strokethrombolysis in the region.
Stroke, Volume 56, Issue Suppl_1 , Page ATP20-ATP20, February 1, 2025. The primary outcome was 3-month functional outcome by modified Rankin scale (mRS). Patients with elevated traditional risk factors at admission may benefit more from thrombolytic therapy compared to those with high inflammatory response indicators.
Stroke, Volume 55, Issue Suppl_1 , Page AWP16-AWP16, February 1, 2024. Introduction:Trials using advanced imaging have shown a benefit from intravenous thrombolysis in patients with wake-up stroke, but real-world data is limited. in those able to receive perfusion imaging). in those able to receive perfusion imaging).
Stroke, Volume 56, Issue Suppl_1 , Page ADP1-ADP1, February 1, 2025. Whether intravenous thrombolysis (IVT) is safe and effective for acute ischemic stroke (AIS) patients with CAA is largely unknown.Methods:This was an explorative analysis of a nationwide database of hospitalizations in the United States.
The goal of the MOST trial was to evaluate argatroban vs. eptifibatide vs. placebo among patients with acute ischemic stroke treated with intravenous thrombolytic therapy.
Stroke, Volume 56, Issue Suppl_1 , Page AWP1-AWP1, February 1, 2025. Background and aims:Central retinal artery occlusion (CRAO) is a rare but significantly underestimated form of ischemic stroke. One of the considered and currently increasingly preferred options is intravenous thrombolysis. years, 46.9%
Stroke, Volume 55, Issue Suppl_1 , Page AWP100-AWP100, February 1, 2024. Introduction:IV thrombolysis is a proven treatment for acute ischemic stroke (AIS), but it is still underutilized in real-world clinical practice. Urgent interventions to increase IV thrombolysis rates are needed to improve acute stroke care.
(MedPage Today) -- LOS ANGELES -- The HOPE trial made another case for extending the therapeutic window for IV thrombolysis in acute ischemic stroke, potentially widening the pool of people eligible for therapy. Among patients with stroke clots.
Stroke, Volume 56, Issue Suppl_1 , Page AWP253-AWP253, February 1, 2025. Background and Aims:Endovascular treatment (EVT) alone has been confirmed to be non-inferior to intravenous thrombolysis (IVT) followed with EVT in acute ischemic stroke (AIS) due to large-vessel occlusion of the anterior circulation.
Stroke, Volume 55, Issue Suppl_1 , Page A43-A43, February 1, 2024. hours of ischemic stroke onset from 2003 to 2021. hours of ischemic stroke onset from 2003 to 2021. Thrombolysis rates and speed of treatment during TS phase I (2010-2013), II (2014-2018), and III (2019-2021) were compared with the pre-TS period (2003-2009).Results:Among
Stroke, Volume 56, Issue Suppl_1 , Page AWP14-AWP14, February 1, 2025. Introduction:The use of IV thrombolysis (IVT) in acute ischemic stroke patients presenting with an NIHSS of 5 has failed to demonstrate benefit, particularly when the symptoms are considered non-disabling. Kappa = 0.26 [95% CI 0.23 0.29]) (Table 1).
Stroke, Volume 56, Issue Suppl_1 , Page AWP6-AWP6, February 1, 2025. Background and Purpose:Whether imaging markers of cerebral small vessel disease on computed tomography (CT-CSVD) relates to early clinical outcomes after intravenous thrombolysis for acute ischemic stroke remains not well understood. 1.95, p = 0.019).Conclusion:This
Stroke, Volume 55, Issue Suppl_1 , Page ATP107-ATP107, February 1, 2024. Introduction:Emergency-department-based implementation strategies to increase thrombolysis are promising. The study population was limited to ischemic stroke patients admitted to the hospital. Among 1608 hospitals, 1131 (70%) had tPA rates below 10%.
Stroke, Volume 56, Issue Suppl_1 , Page AWP19-AWP19, February 1, 2025. We aim to assess the ability of ChatGPT to guide the decision for intravenous thrombolysis (IVT) in patients with acute ischemic strokes (AIS).Methods:The Introduction:Artificial intelligence is emerging as an adjunct promising tool in medicine.
Stroke, Volume 56, Issue Suppl_1 , Page ADP4-ADP4, February 1, 2025. Introduction:Intravenous thrombolysis with alteplase (tPA) or tenecteplase (TNK) is a first-line treatment for acute ischemic stroke. The most serious risk associated with IV thrombolytics is symptomatic intracranial hemorrhage (sICH).
Stroke, Volume 55, Issue Suppl_1 , Page ATP115-ATP115, February 1, 2024. Background:The SouthEast Texas Regional Advisory Council (SETRAC) has actively engaged representatives from regional healthcare systems who collectively work towards advancing stroke care delivery. The rates of thrombolysis increased from 7.10% in 2014 to 11.8%
Stroke, Volume 56, Issue Suppl_1 , Page AWP256-AWP256, February 1, 2025. Introduction:In acute stroke patients who receive revascularization with endovascular thrombectomy (EVT) alone vs intravenous thrombolysis (IVT) followed by EVT, combination treatment has shown improved outcomes measured by the modified Rankin Scale (mRS).
nationwide quality initiative Target: Stroke (TS) is associated with improvement in thrombolysis frequency, timeliness, and outcome, according to a study published online Feb. 7 in JAMA Network Open.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionOver the past decade, stroke management has significantly improved with the widespread use of intravenous thrombolysis (IVT) and the establishment of endovascular thrombectomy (EVT) as the standard of care for increasing patients.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content